A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment

Table 1

Basic characteristics of included studies.

First author

Publication date

NCT number

Nation

Study design

Intervention

Sample size (male)

Age

Outcomes

Follow-up (week)

EG

CG

EG

CG

EG

CG

Kim A Papp

2017

NCT02054481

USA

RCT

Risankizumab; 90 mg; 180 mg

Ustekinumab

41 (30); 42 (29)

40 (27)

F1, F2, F3

12

Kenneth B Gordon

2018

NCT02684370 (UltIMMa-1); NCT02684357 (UltIMMa-2)

USA

RCT

Risankizumab; UltIMMa-1 150 mg; UltIMMa-2 150 mg

Ustekinumab; UltIMMa-1 45 or 90 mg; UltIMMa-2 45 or 90 mg

304 (212); (UltIMMa-1); 294 (203); (UltIMMa-2)

100 (70); (UltIMMa-1); 99 (66); (UltIMMa-2)

(UltIMMa-1); (UltIMMa-2)

(UltIMMa-1); (UltIMMa-2)

F1, F2, F3, F4, F5

52

RCT: randomized controlled trial; EG: experimental group; CG: control group; F1: Psoriasis Area and Severity Index (PASI); F2: adverse events; F3: a static Physician’s Global Assessment (sPGA); F4: quality of life; F5: PS.